• 1. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153
• 5. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577

Methyl 3-fluoro-5-iodo-4-methylbenzoate (CAS No. 861905-21-7): A Key Intermediate in Modern Pharmaceutical Synthesis

Methyl 3-fluoro-5-iodo-4-methylbenzoate, identified by its CAS number 861905-21-7, is a highly versatile and significant compound in the realm of pharmaceutical chemistry. This benzoate derivative features both fluoro and iodo substituents, which make it a valuable intermediate in the synthesis of various biologically active molecules. The presence of these functional groups enhances its reactivity, allowing for diverse chemical transformations that are crucial for developing novel therapeutic agents.

The compound's structure, characterized by a methyl group at the 4-position and an ester moiety at the 3-position, provides a stable backbone for further functionalization. This makes Methyl 3-fluoro-5-iodo-4-methylbenzoate particularly useful in constructing complex molecular architectures. In recent years, there has been a growing interest in fluorinated aromatic compounds due to their improved metabolic stability and enhanced binding affinity to biological targets. The fluoro group, in particular, is known to modulate pharmacokinetic properties, making it a preferred choice for drug design.

The iodo substituent on the benzoate ring adds another layer of utility to this compound. Iodine is a well-established halogen in medicinal chemistry, often employed in cross-coupling reactions such as Suzuki-Miyaura and Stille couplings. These reactions are pivotal in constructing biaryl structures, which are prevalent in many pharmacologically active compounds. The ability to introduce an iodine atom at the 5-position of the benzoate ring allows for subsequent modifications that can lead to the development of new drug candidates with tailored biological activities.

In the context of contemporary pharmaceutical research, Methyl 3-fluoro-5-iodo-4-methylbenzoate has found applications in the synthesis of kinase inhibitors, anticancer agents, and anti-inflammatory drugs. For instance, fluorinated benzene derivatives have been extensively studied for their potential in targeting tyrosine kinases, which are key enzymes involved in cancer cell proliferation. The combination of the fluoro and iodo groups in this compound enables researchers to fine-tune its interactions with these enzymes, leading to more effective therapeutic outcomes.

The ester functionality at the 3-position of Methyl 3-fluoro-5-iodo-4-methylbenzoate also offers opportunities for further chemical manipulation. Esterases can be utilized to hydrolyze this group into a carboxylic acid, providing access to different derivatives with altered pharmacological profiles. This flexibility is particularly valuable in drug discovery pipelines where rapid iteration and optimization are essential.

The synthesis of Methyl 3-fluoro-5-iodo-4-methylbenzoate typically involves multi-step organic transformations that highlight the compound's synthetic utility. Starting from commercially available precursors such as methyl benzoate, fluorination and iodination steps can be performed using established protocols. These reactions often employ palladium catalysts or other transition metals to ensure high regioselectivity and yield. The resulting intermediate can then be further functionalized to meet specific research needs.

The demand for high-quality intermediates like Methyl 3-fluoro-5-iodo strong>-4-methylbenzoate continues to grow as pharmaceutical companies strive to develop innovative therapies. The compound's unique structural features make it an indispensable tool in synthetic chemistry labs worldwide. Researchers leveraging this intermediate can accelerate their drug discovery efforts by accessing a wide range of potential bioactive molecules.

In conclusion, Methyl 3-< strong >fluoro strong > -5 - < strong > iodo strong > -4 -methylbenzoate (CAS No. 861905-21-7) stands out as a critical building block in modern pharmaceutical synthesis. Its combination of functional groups and synthetic accessibility positions it as a cornerstone for developing next-generation therapeutics. As research progresses, the applications of this compound are expected to expand further, solidifying its role as a cornerstone of medicinal chemistry innovation.

• 146014-66-6(Benzoic acid, 2-fluoro-6-iodo-, methyl ester)
• 1149379-04-3(Methyl 6-fluoro-3-iodo-2-methylbenzoate)
• 1417190-32-9(Ethyl 3-fluoro-6-iodo-2-methylbenzoate)
• 625471-27-4(Methyl 2-Fluoro-5-iodobenzoate)
• 1262417-94-6(Methyl 3-fluoro-6-iodo-2-methylbenzoate)
• 501433-13-2(Benzoic acid, 3,6-difluoro-2-iodo-, methyl ester)
• 204257-72-7(Methyl 2-Fluoro-4-iodobenzoate)
• 1202897-48-0(Methyl 5-fluoro-2-iodobenzoate)
• 861905-94-4(3-fluoro-5-iodo-4-methyl-benzoic acid)
• 925215-01-6(2-Fluoro-6-iodo-Benzoic Acid Ethyl Ester)